Development of Orally Bioavailable Bicyclic Pyrazolones as Inhibitors of Tumor Necrosis Factor-α Production
- 24 April 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (11) , 2724-2727
- https://doi.org/10.1021/jm049968m
Abstract
2-Aryl-3-pyrimidinyl based tumor necrosis factor-α (TNF-α) inhibitors, which contain a novel bicyclic pyrazolone core, are described. Many showed low-nanomolar activity against lipopolysaccharide-induced TNF-α production in monocytic cells. Secondary screening data are presented for the pyrimidinyl bicyclic pyrazolones. Several of these analogues showed good oral bioavailability in rat and efficacy in the rat iodoacetate in vivo model.Keywords
This publication has 9 references indexed in Scilit:
- The Protein Kinase Complement of the Human GenomeScience, 2002
- MAP KinasesChemical Reviews, 2001
- Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein KinaseJournal of Medicinal Chemistry, 1999
- The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid ArthritisDrugs, 1998
- The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinaseChemistry & Biology, 1997
- Cytokines in autoimmunityCurrent Opinion in Immunology, 1996
- 2,4,5- triarylimidazole inhibitors of IL-1 biosynthesisBioorganic & Medicinal Chemistry Letters, 1995
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans As cell-viability indicatorsBioorganic & Medicinal Chemistry Letters, 1991